Table 4.

Clinical trials of therapeutic and diagnostic modalities for DVT management.

Therapeutic / diagnostic modality	Description	Possible outcomes	Status
Low molecular weight heparin	Anticoagulant for DVT in cancer patients	Recurrent DVT/PE, bleeding	Phase IV recruiting
Fondaparinux sodium and Un-fractionated heparin	Evaluate the efficacy in subjects with acute symptomatic DVT	–	Phase III completed
Warfarin	Oral anticoagulant for idiopathic DVT	Recurrent venous thromboembolism, hemorrhage	Phase IV completed
Dalteparin and Warfarin	Anticoagulant for effective catheter preservation	Recurrent DVT/PE, bleeding	Phase II completed
Dalteparin sodium injection	Anticoagulant for long-term treatment of DVT	–	Phase IV completed
Clopidogrel	Inhibit platelet aggregation in coronary artery stent thrombosis	Prevalence of genetic polymorphisms influencing pharmacokinetics	Phase IV completed
Tinzaparin sodium	Anticoagulant for long-term treatment of proximal venous thrombosis	Recurrent venous thromboembolism, bleeding	Phase IV completed
Rosuvasratin and Enoxaparin	Prevention of DVT occurrence based on inhibition of HMO-co-A reductase (statin)	Development of DVT	Phase IV recruiting
Catheter-directed thrombolysis	DVT treatment	Bleeding, prevalence of vein anomalies, underlying thrombophilia	Ongoing, not recruiting
D-dimer and Ultrasound	Diagnosis of DVT	–	Completed
Doxil, DaunoXome, or Abraxane	Liposomal nanoparticle formulations for possible use for DVT management	–	FDA approved